RIPK1 and neoplasm: Decreased levels of these kinases align with our observations of decreased RIPK1 S25 phosphorylation following T cell treatment in sensitized tumor cells, indicating that loss of checkpoint kinase recruitment to complex I may be a putative mechanism driving tumor sensitivity to T cell attack.